Nektar Therapeutics NKTR EBITDA margin

EBITDA margin at other companies

AmgenAMGN

42.2%+3.0pp

Regeneron PharmaceuticalsREGN

28.1%-2.5pp

ImmunityBio, Inc.IBRX

-174%-78.2pp

Viridian Therapeutics, Inc.VRDN

-569%-284pp

Kymera TherapeuticsKYMR

-325.7%-112pp

Shattuck Labs, Inc.STTK

-4,902.1%-9,075pp

FAQ

What is Nektar Therapeutics's EBITDA margin?

Nektar Therapeutics (NKTR) reported EBITDA margin of -240.6% in Q1 2026.

How has Nektar Therapeutics's EBITDA margin changed year-over-year?

Nektar Therapeutics's EBITDA margin decreased by 67.4% year-over-year, from -143.8% to -240.6%.

What is the long-term trend for Nektar Therapeutics's EBITDA margin?

Over 5 years (2020 to 2025), Nektar Therapeutics's EBITDA margin has grown at a -1.3% compound annual growth rate (CAGR), from -268.7% to -251.8%.

What does EBITDA margin mean?

EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.